IND cleared for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies February 1, 2023
FDA Clears IND Application for Ph 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors February 1, 2023
Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer announced February 1, 2023
FDA clears IND for Novel Bispecific CAR IMPT-314 to Treat Aggressive B-cell Lymphoma February 1, 2023
FDA Accelerated Approval of TUKYSA® (tucatinib) + Trastuzumab in Previously Treated RAS WT, HER2-Positive mCRC Patients February 1, 2023
FDA Approves KEYTRUDA® as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB, II, or IIIA NSCLC February 1, 2023
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer February 1, 2023
